Pharmaceutical News

RSS

Researchers report new breakthrough in countering deadly effects of radiation exposure

An interdisciplinary research team led by The University of Texas Medical Branch at Galveston reports a new breakthrough in countering the deadly effects of radiation exposure. A single injection of a regenerative peptide was shown to significantly increase survival in mice when given 24 hours after nuclear radiation exposure.

24 Aug 2015

Alpha lipoic acid can stimulate telomerase with positive effects in mouse model of atherosclerosis

In human cells, shortened telomeres, the protective caps at the ends of chromosomes, are both a sign of aging and contribute to it. Scientists at Emory University School of Medicine have found that the dietary supplement alpha lipoic acid (ALA) can stimulate telomerase, the enzyme that lengthens telomeres, with positive effects in a mouse model of atherosclerosis.

24 Aug 2015

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics, an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug Designation for MTG-201, an advanced biologic therapy targeting Dickkopf-3 gene defects in various cancers, for the treatment of malignant mesothelioma.

23 Aug 2015

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

21 Aug 2015

Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species, reported researchers from the Perelman School of Medicine at the University of Pennsylvania.

21 Aug 2015

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid is expected to save billions of dollars a year as patents for several blockbuster antipsychotic medications expire and use of generic versions of these drugs increases, according to a new study by researchers at the University of Maryland School of Medicine. These savings may provide relief from the high costs of these medications and allow policymakers to lift restrictions on patients' access, the researchers argue.

21 Aug 2015

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company Specialised Therapeutics Australia Pty (STA) to market and distribute the drug candidate APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.

20 Aug 2015

New scientific conference 'Aspirin in the 21st Century' to be held in London

What more can be said about aspirin, a medicine that was first prescribed at the end of the 19th century? It is known and accepted in every country. For over a hundred years it has been the standard by which all other, newer, painkillers have had to be judged, and it has never been found to be inferior. It is still considered the world's leading analgesic.

20 Aug 2015

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

IQWiG finds no added benefit for safinamide in Parkinson disease

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.

20 Aug 2015

GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

New analyses from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) will be presented at ESC Congress 2015 to be held in London, United Kingdom, from August 29 to September 2, 2015.

20 Aug 2015

Experimental MERS-CoV vaccine shows promise in monkeys and camels

National Institutes of Health scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels.

20 Aug 2015

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira today announced that Inflectra (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia. This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS).

20 Aug 2015

Women's contraceptive choices often driven by relationships, sexual activity

Women's contraceptive choices are more often driven by current relationships and sexual activity than by long-term pregnancy intentions, according to Penn State College of Medicine researchers.

19 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA.

19 Aug 2015

Even the Score issues statement on FDA approval of flibanserin for treatment of women with HSDD

Even the Score issued the following statement following today's historic approval by the Food and Drug Administration of flibanserin (Addyi), the first-ever medical treatment option for women's most common sexual dysfunction, known as Hypoactive Sexual Desire Disorder (HSDD).

18 Aug 2015

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that Takeda Pharmaceutical Co.'s $2.37 billion settlement didn't attract enough claimants to participate in the deal, which said the company would fund the deal after 95% of claimants joined it.

18 Aug 2015

Pharmaceutical News

Researchers report new breakthrough in countering deadly effects of radiation exposure

Alpha lipoic acid can stimulate telomerase with positive effects in mouse model of atherosclerosis

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Novel synthetic DNA vaccine induces protective immunity against MERS virus in animal study

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

PharmaMar to market and distribute APLIDIN drug candidate in Australia, New Zealand

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

New scientific conference 'Aspirin in the 21st Century' to be held in London

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

IQWiG finds no added benefit for safinamide in Parkinson disease

GARFIELD-AF data to demonstrate impact of antithrombotic treatment patterns on AF patients at ESC Congress 2015

Experimental MERS-CoV vaccine shows promise in monkeys and camels

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Women's contraceptive choices often driven by relationships, sexual activity

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Even the Score issues statement on FDA approval of flibanserin for treatment of women with HSDD

Takeda's $2.37 billion settlement over Actos didn't attract enough claimants to participate in the deal

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News